BBBoyang Bian

Boyang Bian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Boyang Bian has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A comparative effectiveness analysis of fumarates versus cladribine in people with MS transitioning from anti-CD20 therapies

    by Regina Berkovich, Daniel Bandari, Donald Negroski, Thomas P. Leist, Devon S. Conway, Tyler Kaplan, Daniel Long, Salvatore Napoli, Irena Dujmovic Basuroski, Simran Mangat, et al.

  • Time-dependent divergence in infection risks among patients with multiple sclerosis treated with fumarates versus anti-CD20 monoclonal antibodies

    by Kyle Smoot, Erin E Longbrake, Mirla Avila, Sarah F Wesley, Afif Hentati, William Meador, John Scagnelli, Lynsey L Lakin, Mark Gudesblatt, Boyang Bian, et al.

    Background: People with multiple sclerosis (pwMS) treated with anti-CD20 monoclonal antibodies have an elevated infection risk, yet long-term comparative data with oral fumarates are limited. Objective: To compare infection incidence, healthcare resource utilization, and relapse outcomes among pwMS receiving fumarate or anti-CD20 therapy for ⩾2 years. Methods: This retrospective propensity-matched (1:2) analysis used US Komodo Health claims (1 January 2016–31 May 2022) for pwMS aged 18–64 years with ⩾2 years of continuous follow-up. Outcomes were assessed using Poisson generalized linear models. Results: A total of 1956 pwMS were matched (fumarates: n = 652; anti-CD20s: n = 1304), with mean follow-up ~3 years. By year 2, the fumarates group had a lower infection rate than anti-CD20s (rate ratio: 0.84; 95% CI: 0.73–0.97; p = 0.016), but the most substantial difference was observed in years 4+, where fumarate-treated patients had a 30% reduction versus anti-CD20s (rate ratio: 0.70; 95% CI: 0.52–0.95; p = 0.021). Conclusions: Fumarate therapy was associated with a lower infection risk versus anti-CD20s. The infection rate in the fumarates group remained relatively stable over time, but it progressively increased in the anti-CD20 group, with the most prominent differences observed at year 4 and beyond.

  • Open Access

    Natalizumab is associated with improved relapse outcomes and lower healthcare utilization versus ocrelizumab in treatment-naïve people with multiple sclerosis

    by Jeffrey Kaplan, Dana Beenstock, Martin Belkin, Heidi Crayton, Christopher Eckstein, Ruth Fredericks, Boyang Bian, Nicholas Belviso, Daphne Ni, Danette Rutledge

    Natalizumab (NTZ) and ocrelizumab (OCR) are well-established therapies and commonly considered first-line for newly diagnosed people with multiple sclerosis (pwMS) in the United States. However, there is a paucity of data comparing healthcare resource utilization (HCRU) and relapse outcomes between NTZ and OCR in this population. This retrospective longitudinal analysis using the Komodo Health Claims Database included newly diagnosed treatment-naïve pwMS aged 18-64 years with ≥1 prescription claims for NTZ or OCR between 1 January 2017 and 31 March 2022. Propensity score matching (1:2) was used to balance baseline characteristics. Outcomes included HCRU and costs, as well as relapses. Relapse events were identified using a claims‑based algorithm. The analysis included 1,261 NTZ- and 2,522 OCR-treated pwMS. First-line NTZ treatment was associated with significantly lower annualized rates of all-cause inpatient admissions (rate ratio = 0.61, 95% CI = 0.44-0.85; p = 0.003) and costs as well as emergency department visits (rate ratio = 0.80, 95% CI = 0.68-0.96; p = 0.015) than first-line OCR treatment. Annualized relapse rates (ARR) were significantly lower with first-line NTZ versus OCR treatment (0.20 vs. 0.28; rate ratio = 0.70, 95% CI = 0.59-0.82; p < 0.001). There was also a significantly higher probability of pwMS being relapse-free at 3 years with first-line NTZ versus OCR (69.9% vs. 63.9%; p = 0.002). This study has limitations inherent to claims data, including limited clinical detail and reliance on a claims-based relapse algorithm. This real-world, claims-based analysis demonstrates that first-line NTZ treatment was associated with significantly lower inpatient and emergency department HCRU, inpatient healthcare costs, and ARR than first-line OCR treatment. Given the paucity of comparative data among these therapies in newly diagnosed MS patients, these results provide valuable real-world evidence to help guide treatment decisions in this group.

  • Open Access

    Comparative Effectiveness and Risk of Severe Infection in Adult Patients With MS Treated With Diroximel Fumarate Versus Anti-CD20 Monoclonal Antibodies: A Real-World Claims Analysis

    by Ahmed Z. Obeidat, Michelle Betz, Rebecca Straus Farber, Erica Goff, Mark Gudesblatt, Le H. Hua, Yang Mao-Draayer, Derrick Robertson, Jonathan D. Santoro, Tony Wang, et al.

    Introduction Multiple sclerosis (MS) is a chronic, immune-mediated neurological disease, leading to significant morbidity. Over 25 disease-modifying therapies (DMTs) are approved for MS; however, older patients may benefit less from high-efficacy DMTs. We compared the risk of severe infections (SIs) and annualized relapse rate (ARR) by age (< 45 and ≥ 45 years) between diroximel fumarate (DRF) and anti-CD20 monoclonal antibodies (mAbs) in patients with MS. Methods This retrospective study utilized the Komodo Health Claims database to identify patients treated with DRF or anti-CD20 agents. Patients were propensity score matched 1:1 on baseline characteristics and stratified by age (younger: < 45 years; older: ≥ 45 years). Infection-related encounters were identified by diagnosis codes; SIs required hospitalization or intravenous antibiotics. MS relapses were based on inpatient or outpatient claims and associated treatments. Results Between 2016 and 2025, 2894 propensity score-matched patients with MS who initiated DRF (n = 1447) or anti-CD20s (n = 1447) were included. DRF-treated patients had a lower proportion of SIs at 12 and 24 months compared with anti-CD20-treated patients (p ≤ 0.002 at 24 months). Younger DRF-treated patients had significantly fewer SIs (p = 0.005), while older DRF-treated patients had lower non-SI rates. COVID-19-related SIs were also significantly lower in DRF-treated patients (p < 0.001). ARRs were similar between the two groups. Conclusion DRF-treated patients with MS had a significantly lower risk of SI compared with anti-CD20-treated patients, with no difference in ARR. More real-world studies are needed to understand the efficacy and safety of DMTs in the setting of de-escalation in aging patients with MS.


  • Open Access

    Comparative Effectiveness of Fumarates Versus Sphingosine-1-Phosphate Receptor Modulators in Black Patients with Multiple Sclerosis

    by Sophia Woodson, Edward J. Gettings, Chu-Yueh Guo, Sylvia Klineova, Jong-Mi Lee, Rebecca S. Romero, Aljoeson Walker, Nicholas Belviso, Sai L. Shankar, Jason P. Mendoza, et al.

    Introduction Multiple sclerosis (MS) is a heterogeneous disease that disproportionately impacts Black people with MS (PwMS), who experience more severe disease and higher relapse rates compared with non-Black populations. Despite widespread use of fumarates and sphingosine-1-phosphate (S1P) receptor modulators as oral disease-modifying therapies (DMTs) for relapsing MS, their comparative effectiveness in Black PwMS has not been studied. This study aims to help address this gap using real-world claims data. Methods This retrospective analysis using the Komodo Health Claims Database included Black PwMS. Patients were aged 18–64 years with ≥ 1 claim for MS diagnosis (International Classification of Diseases, Tenth Revision, Clinical Modification code G35) and ≥ 1 prescription claim for fumarates (dimethyl fumarate or diroximel fumarate) or an S1P receptor modulator (fingolimod, siponimod, ozanimod, or ponesimod) between January 2017 and April 2023. Outcomes included annualized relapse rate (ARR) and time to first relapse. Propensity score matching (2:1) and inverse probability weighting were used to balance baseline characteristics. Relapse events were identified using a claims-based algorithm. Results The analysis included 1664 Black PwMS (1231 and 433 in fumarate and S1P treatment arms, respectively). Post-index ARRs were comparable between groups (rate ratio [RR] 1.18, p = 0.423). Kaplan–Meier analyses showed similar relapse-free proportions at 24 months (72.6% and 74.7% in fumerate and S1P populations, respectively; p = 0.152). These findings were consistent in both the propensity score-matched and inverse probability weighted populations. Conclusions This real-world, claims-based analysis demonstrates that fumarates and S1P receptor modulators have similar effectiveness in reducing relapses among Black PwMS, with > 72% of patients in both treatment groups remaining relapse-free at 24 months. Given the underrepresentation of Black patients in MS clinical trials, these results provide valuable real-world evidence to guide treatment decisions for this population.

  • Open Access

    Real-World Treatment Outcomes in Black, Hispanic, Asian, and White Patients with Multiple Sclerosis Treated with Natalizumab

    by Karen Blitz-Shabbir, Aimee M. Banks, Hina Garg, Flavia Nelson, Suma Shah, Nicholas Belviso, Jason P. Mendoza, Robin L. Avila, Boyang Bian, Kinyee Fong

    Background Multiple sclerosis (MS) is a heterogeneous disease that may manifest differently among racial/ethnic groups, influencing response to disease-modifying therapy (DMT). Data on natalizumab (NTZ) effectiveness in people with MS (PwMS) based on race/ethnicity are limited. Objective The aim of this study was to evaluate the effectiveness of NTZ on relapse onset and rate, and to assess MS-related healthcare encounters and costs in Black, Hispanic, Asian, and White PwMS. Methods This was a retrospective analysis of the Komodo Health Claims Database, including adult patients in the US with one or more MS claim at index date (January 1, 2016–August 31, 2022). Patients were followed from first NTZ exposure through end of study, end of insurance eligibility, gap in index DMT > 45 days, or DMT switch. Annualized relapse rate (ARR), time to first relapse, and MS-related healthcare encounters and costs were compared in the 12 months pre/post NTZ initiation and while on treatment across racial strata. Results The study included 3244 PwMS (Black, n = 632; Hispanic, n = 382; Asian, n = 49; White, n = 2181). Mean post-index NTZ exposure was 15.5–19.2 months. Post-index ARRs were significantly reduced across racial/ethnic groups (p < 0.001). The adjusted Kaplan-Meier estimated proportion of relapse-free patients at 2 years for all racial/ethnic groups was not significantly different from the White group. Significant differences were observed in annualized MS-related healthcare cost rates but not in annualized MS-related encounter rates before and after NTZ initiation across the racial/ethnic groups. Conclusion NTZ was effective across racial/ethnic groups although not significantly different between groups.

  • Open Access

    Safety of long-acting beta agonists and inhaled corticosteroids in children and adolescents with asthma

    by Ying Xia, Christina M. L. Kelton, Liang Xue, Jeff J. Guo, Boyang Bian, Patricia R. Wigle

    The introduction of long-acting beta agonists (LABAs) was considered a major advance in bronchodilator therapy for adult, as well as pediatric, patients with asthma. However, the use of LABAs has raised safety concerns, especially the potential for severe asthma exacerbations (SAEs) resulting in hospitalizations or even death. Meanwhile, the use of inhaled corticosteroids (ICSs), a cornerstone in the treatment of mild-to-severe persistent asthma, has been associated with growth suppression in children. The purpose of this review was to identify and discuss the major published safety studies surrounding LABA, ICS, and combined LABA/ICS usage in children. By way of a critical search for influential published clinical trials, meta-analyses, and observational studies, six studies relevant to the safety of LABA monotherapy, seven studies relevant to ICS monotherapy, and four studies on the subject of LABA/ICS combination usage were identified and reviewed. Based on the reviewed literature, the controversy surrounding these anti-asthma medications was clearly exposed. On the one hand, there is some evidence that LABA monotherapy may be associated with SAEs and asthma-related death, while ICS monotherapy may be associated with a higher risk of growth suppression. On the other hand, the concurrent use of a LABA with an ICS has been associated with positive outcomes including symptom reduction and reduced rate and severity of exacerbations. Further clinical research is warranted and has been called for by the US Food and Drug Administration.